Guardant Health (GH) Stock
Key stats
- Market cap
- $20.94B
- Price / Earnings ratio
- -43.3x
- EPS (TTM)
- -$3.68
- Volume
- Loading
- 52-week high
- $191.05
- 52-week low
- $74.55
Source: third-party data provider, as of November 13, 2026
Compare with GH
Recent news
Kevin Sayer Joins Guardant Health Board of Directors
Kevin Sayer Joins Guardant Health Board of Directors
GH
Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test
Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test
GH
Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
GH
Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians
Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians
GHNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 40.93
- MACD 12/26/9
- -3.36
- EMA 9 of MACD
- -1.20
- MACD histogram
- -2.16
- SMA 50
- $169.00
- Price below SMA 50
- EMA 50
- $165.86
- Price below EMA 50
- SMA 200
- $132.35
- Price above SMA 200
- EMA 200
- $137.08
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.68 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Kevin Sayer Joins Guardant Health Board of Directors
Kevin Sayer Joins Guardant Health Board of Directors
GHGuardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test
Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test
GHGuardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
GHGuardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians
Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians
GH
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
GH
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
GH
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
GH
Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
GH
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
GH
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
GHNews tone: automated (AI) classification of the article's content, not a price prediction.
About Guardant Health
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Helmy Eltoukhy Ph.D. | Co-Founder, Co-CEO & Chairman | 1979 |
| Dr. AmirAli Talasaz Ph.D. | Co-CEO & Director | 1980 |
| Mr. Michael Bell | Chief Financial Officer | 1969 |
| Dr. Darya Chudova | Chief Technology Officer | 1974 |
| Mr. John G. Saia J.D. | Chief Legal Officer & Corporate Secretary | 1973 |
| Mr. Andy Ament | Senior Vice President of Operations | — |
| Mr. Robert Parks | Senior VP & Chief Accounting Officer | — |
| Mr. Kumud Kalia | Chief Information Officer | 1966 |
| Zarak Khurshid | Vice President of Investor Relations | — |
| Ms. Gulshan Shaver J.D. | Senior VP of Legal Affairs & Chief Compliance Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 40.93
- MACD 12/26/9
- -3.36
- EMA 9 of MACD
- -1.20
- MACD histogram
- -2.16
- SMA 50
- $169.00
- Price below SMA 50
- EMA 50
- $165.86
- Price below EMA 50
- SMA 200
- $132.35
- Price above SMA 200
- EMA 200
- $137.08
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $190.00
- Average
- $206.00
- High
- $225.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +1.4 | +2.4 | ||||||||||
| 2022 | -30.8 | -9.2 | -0.1 | -15.5 | -34.1 | +4.4 | +14.9 | +3.5 | +9.7 | -9.7 | +5.5 | -48.1 |
| 2023 | +16.4 | -3.5 | -20.2 | -6.2 | +30.3 | +14.0 | +10.4 | +2.8 | -15.3 | -11.3 | -4.0 | +2.7 |
| 2024 | -17.3 | -13.4 | +8.8 | -11.1 | +48.4 | +5.4 | +24.3 | -23.3 | -6.6 | -1.1 | +54.8 | -14.0 |
| 2025 | +47.9 | -10.6 | +4.6 | +11.2 | -16.9 | +23.6 | -19.2 | +62.8 | -6.1 | +48.5 | +9.6 | -2.9 |
| 2026 | +12.1 | -18.3 | +0.2 | -4.5 | +48.0 | +16.2 | -5.1 | +0.1 | +8.5 | +2.3 | -9.3 |
